Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) (NCT05490446).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:16 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Agios publicly reported a trial-specific Phase 2a readout for NCT05490446 and explicitly framed it as positive: “clinical proof-of-concept,” with “favorable efficacy” and a “positive benefit-risk profile,” then advanced the program into Phase 2b. That is a clear positive public readout for this Phase 2 study.

Sources
Sponsorinvestor.agios.com11/20/23
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios said clinical proof-of-concept was achieved in Phase 2a; based on favorable efficacy and a positive benefit-risk profile, it planned to advance AG-946 into Phase 2b.

View source
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes

ClinicalTrials.gov identifies NCT05490446 as the Phase 2a/2b AG-946/tebapivat study in lower-risk MDS, matching the trial named in the Agios Phase 2a readout.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Agios publicly reported a trial-specific Phase 2a readout for NCT05490446 and explicitly framed it as positive: “clinical proof-of-concept,” with “favorable efficacy” and a “positive benefit-risk profile,” then advanced the program into Phase 2b. That is a clear positive public readout for this Phase 2 study.

Found Apr 1, 2026, 7:16 PMOutcome date Nov 20, 2023, 12:00 AMReviewed Apr 1, 2026, 7:18 PM
Sponsorinvestor.agios.comNov 20, 2023, 12:00 AM
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
Agios said clinical proof-of-concept was achieved in Phase 2a; based on favorable efficacy and a positive benefit-risk profile, it planned to advance AG-946 into Phase 2b.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
ClinicalTrials.gov identifies NCT05490446 as the Phase 2a/2b AG-946/tebapivat study in lower-risk MDS, matching the trial named in the Agios Phase 2a readout.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:18 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)93% confidenceReviewed Apr 1, 2026, 7:18 PM

Agios publicly reported a trial-specific Phase 2a readout for NCT05490446 and explicitly framed it as positive: “clinical proof-of-concept,” with “favorable efficacy” and a “positive benefit-risk profile,” then advanced the program into Phase 2b. That is a clear positive public readout for this Phase 2 study.